Omnio is preparing for taking the company to the next phase of development with newly appointed board
Omnio AB, a private biopharmaceutical company developing recombinant plasminogen for chronic non-healing wounds, announces the inauguration of a new board of directors that bring...
Omnio raises 1.5M EUR in successful series A funding.
Omnio AB, a private biopharmaceutical company developing recombinant plasminogen to heal chronic wounds announces a successful 1.5M EUR funding round. The funds will be allocated...
Omnio and its collaborators receives a 4.95 MSEK grant from VINNOVA, Sweden's innovation agency, for the project "Development of a new biological treatment for diabetic foot ulcers".
Vinnova has granted Omnio and its partners 4.95 million SEK to develop a safe, scalable and cost-effective biological drug and to conduct the preclinical development that will al...
Omnio AB raises 5.5MSEK in fundraising round
SWEDEN, 6th December, 2021 - Omnio AB is developing new drug products based on the pro-inflammatory and immune regulatory effects of the serum protein plasminogen. During fall th...
Omnio AB receives patent for use of inhibitors of plasminogen for treating, reducing or preventing radiation-induced injuries
Omnio receives patent approval for use of tranexamic acid (TXA) to treat, reduce and prevent radiation induced injuries. TXA is a synthetic reversible competitive inhibitor to th...
Research group at Umeå University publishes paper on the regulation of wound healing by the plasminogen receptor, Plg-RKT
The authors show that Plg-RKT is a new regulator participating in different phases of cutaneous burn wound healing, which coordinately plays a role in the interrelated responses...
Omnio AB receives support from SweLife together with Umeå University and the county of Västerbotten to develop biological treatments for periodontitis and peri-implantitis
Omnio together with Umeå university and the county council selected by the Vinnova program SweLife receive support of a total of SEK 3 million to develop new treatments for perio...
Research group at Umeå University publishes paper on Plasminogens role in radiation induced dermatitis
Skin damage caused by radiation therapy (radiodermatitis) is a severe side effect of radiotherapy in cancer patients, and there is currently a lack of effective strategies to pre...
Professor Tor Ny receives a 6 MSEK grant from the Erling-Persson foundation over three years for the project "Plasminogen: a novel pro-inflammatory drug to combat infections by antibiotic-resistant bacteria"
Since their discovery, antibiotics have been "wonder drugs" to combat bacterial infections and thereby have saved millions of lives. However, an alarming consequence of increasin...
Professor Tor Ny publish article in Thrombosis and Haemostasis on Plasminogens role in cutaneous wound healing
In the paper, Sulniute et al. show that plasminogen is transported to the wound by inflammatory cells early during the healing process, where it potentiates inflammation and how...
Om Omnio
Webbplats
www.omnio.se
Prenumerera
Få löpande information från Omnio via e-post.
Handelsinformation
Marknad
Onoterat